Abstract
High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 61-70 |
| Number of pages | 10 |
| Journal | CNS oncology |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- glioblastoma
- high-grade gliomas
- overall survival
- progression-free survival
- recurrence treatment
ASJC Scopus subject areas
- Medicine(all)
Cite this
Treatment options for recurrent high-grade gliomas. / Birk, Harjus S.; Han, Seunggu (Jude); Butowski, Nicholas A.
In: CNS oncology, Vol. 6, No. 1, 01.01.2017, p. 61-70.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Treatment options for recurrent high-grade gliomas
AU - Birk, Harjus S.
AU - Han, Seunggu (Jude)
AU - Butowski, Nicholas A.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.
AB - High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.
KW - glioblastoma
KW - high-grade gliomas
KW - overall survival
KW - progression-free survival
KW - recurrence treatment
UR - http://www.scopus.com/inward/record.url?scp=85050579807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050579807&partnerID=8YFLogxK
U2 - 10.2217/cns-2016-0013
DO - 10.2217/cns-2016-0013
M3 - Review article
C2 - 28001091
AN - SCOPUS:85050579807
VL - 6
SP - 61
EP - 70
JO - CNS oncology
JF - CNS oncology
SN - 2045-0915
IS - 1
ER -